Redeye comments on Faron’s ASCO 2025 presentation of full phase II BEXMAB data in high-risk MDS. The results confirm and extend previously reported topline findings, demonstrating strong and durable efficacy in both frontline and relapsed/refractory patient populations. With a median overall survival nearly doubling historical benchmarks in r/r MDS and a 56% cCR rate in frontline patients, we argue that the data reinforces bexmarilimab’s best-in-class potential.
LÄS MER
